Literature DB >> 23558525

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.

X Leleu1, G Fouquet, B Hebraud, M Roussel, D Caillot, M L Chrétien, B Arnulf, R Szalat, L Garderet, L Benajiba, B Pegourie, C Regny, B Royer, A Caulier, A M Stoppa, S Garciaz, C Touzeau, C Chaleteix, J P Fermand, H A Loiseau, T Facon, M Attal, P Moreau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558525     DOI： 10.1038/leu.2013.101

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Authors:  Pieter Sonneveld; Emilie Asselbergs; Sonja Zweegman; Bronno van der Holt; Marie Jose Kersten; Edo Vellenga; Marinus van Marwijk-Kooy; Annemiek Broyl; Okke de Weerdt; Sarah Lonergan; Antonio Palumbo; Henk Lokhorst
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

Review 2.  First line vs delayed transplantation in myeloma: Certainties and controversies.

Authors:  Annamaria Brioli
Journal:  World J Transplant       Date:  2016-06-24

Review 3.  Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Authors:  M Mohty; P G Richardson; P L McCarthy; M Attal
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

4.  Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.

Authors:  H Einsele; S Knop; M Vogel; J Müller; M Kropff; B Metzner; C Langer; H Sayer; W Jung; H A Dürk; H Salwender; H Wandt; F Bassermann; M Gramatzki; W Rösler; H-H Wolf; W Brugger; M Engelhardt; T Fischer; P Liebisch; C Straka
Journal:  Leukemia       Date:  2017-03-15       Impact factor: 11.528

Review 5.  Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Authors:  Mohamad Mohty; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

6.  Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.

Authors:  Anne Lok; Julie Mocquard; Jessie Bourcier; Laurence Redelsperger; Antoine Bonnet; Cecile Chauvin; Patrick Thomaré; Beatrice Mahé; Cyrille Touzeau; Philippe Moreau
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

Review 7.  Fixed duration vs continuous therapy in multiple myeloma.

Authors:  Heinz Ludwig; Niklas Zojer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.

Authors:  Shuichiro Takashima; Toshihiro Miyamoto; Masanori Kadowaki; Yoshikiyo Ito; Takatoshi Aoki; Ken Takase; Takahiro Shima; Goichi Yoshimoto; Koji Kato; Tsuyoshi Muta; Motoaki Shiratsuchi; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Tomohiko Kamimura; Koichi Akashi
Journal:  Int J Hematol       Date:  2014-06-14       Impact factor: 2.490

9.  VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

Authors:  E Terpos; D Christoulas; E Kastritis; M Roussou; M Migkou; E Eleutherakis-Papaiakovou; M Gavriatopoulou; M Gkotzamanidou; N Kanellias; E Manios; C Papadimitriou; M A Dimopoulos
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

10.  The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Ann Hematol       Date:  2020-10-29       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.